What question did this study set out to answer?

December 10, 2008Thrombosis and Haemostasis

VTE recurrence in patients with inherited deficiencies of natural anticoagulants

View Full Paper

Ask AI

Bookmark

Why the study?

Does prolonged oral anticoagulant therapy prevent VTE recurrence in patients with inherited deficiencies of natural anticoagulants?

Population

Patients with venous thromboembolism and inherited deficiencies of natural anticoagulants

Design

Editorial

Authors

MGMonica GianniUniversity of Insubria FDFrancesco DentaliMario Negri Institute for Pharmacological Research

Discussion

Member takes

Implication

The editorial highlights the uncertainty and lack of robust data regarding the risk of VTE recurrence in patients with inherited deficiencies of natural anticoagulants, emphasizing the need for further research to guide optimal anticoagulation duration.

Key Points

To evaluate the risk of recurrent venous thromboembolism in patients with inherited deficiencies of natural anticoagulants and assess evidence guiding the duration of secondary anticoagulation.
Synthesized observational cohort data and clinical literature evaluating long-term recurrence rates following an initial episode of venous thromboembolism.
Assessed recurrence predictors including clinical triggers, persistent cancer, residual venous thrombosis, post-anticoagulation D-dimer, and inherited thrombophilias such as antithrombin, protein C, and protein S deficiencies.
Cumulative recurrence rates after stopping oral anticoagulation range from 10.1% to 17.5% at two years and reach approximately 30.3% to 30.4% at eight to ten years.
Inherited deficiencies of antithrombin, protein C, and protein S are identified in under 10% of venous thromboembolism cases, but current recurrence studies remain underpowered and show similar recurrence risks to non-deficient controls.
Persistent active cancer confers a 10% to 20% first-year recurrence risk, and abnormal post-anticoagulation D-dimer levels significantly predict recurrence, whereas common defects like factor V Leiden confer only modest risk.

Structured PICO

Does prolonged oral anticoagulant therapy prevent VTE recurrence in patients with inherited deficiencies of natural anticoagulants?

Population

Patients with venous thromboembolism (VTE) and inherited deficiencies of natural anticoagulants (antithrombin, protein C, and protein S)

Intervention

Oral anticoagulant therapy (OAT)

Outcome

VTE recurrencehard clinical

Cite This Study

Gianni et al. (2008) studied this question.

synapsesocial.com/papers/6a70fd2ce71d69abee08fa37 https://doi.org/10.1160/th08-11-0763

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

VTE recurrence in patients with inherited deficiencies of natural anticoagulants

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

VTE recurrence in patients with inherited deficiencies of natural anticoagulants

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider